Viridian Therapeutics Inc —— 季度现金流量表 (NASDAQ:VRDN) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 742.4 M660.98 M582.32 M577.14 M899.42 M 负债总额 70.76 M56.51 M67.16 M74.17 M177.25 M 权益总额 671.64 M604.47 M515.17 M502.97 M722.17 M 负债及股东权益总额 742.4 M660.98 M582.32 M577.14 M899.42 M 总债务 20.58 M20.68 M20.79 M20.89 M84.18 M 净债务 -697.02 M-615.91 M-542.61 M-470.01 M-790.52 M

新闻

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN)

Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-04-02

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

Viridian Therapeutics在Leerink会议上展望市场扩张

Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion

Viridian Therapeutics在TD Cowen会议上的发言:甲状腺眼病治疗领域的战略布局

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment

Stifel重申Viridian Therapeutic股票评级,关注生物制品许可申请审查